Uremic patients seem to have two opposite aspects in tivity may be a potential cause of thrombosis in uremic patients.
hemostatic status, which are bleeding and thrombotic statistics suggest that uremic patients have a high inciMethods. The subjects were pre-dialyzed patients, patients dence of thrombotic events [7, 8] . Moreover, a thromunder hemodialysis (HD) or continuous ambulatory peritoneal botic tendency, caused by factors such as platelet hyperdialysis (CAPD) therapy, and age-matched healthy controls. aggregability and hypercoagulability, has been described Analyses of PMPs were performed using a flow cytometer. Annexin V was used to probe procoagulant activity of PMPs. The in dialysis patients [9] [10] [11] [12] . This evidence emphasizes that impacts of the HD procedure, arteriovenous (AV) fistula, and acute arterial occlusion can be facilitated under a uremic recombinant human erythropoietin (rHuEPO) treatment on situation. However, to our knowledge there are no studthe release of PMPs were additionally assessed.
ies giving a definite answer to the question of why uremic lytic surface for the prothrombinase reaction, contributing to the acceleration of thrombin generation [13, 14] . Thus, PMPs may play a pivotal role in acute arterial occlusion in atherosclerotic small arteries or arterioles where pathological levels of fluid shear stress may occur and acute myocardial infarction [22] . In addition, PMPs that adhered to vascular endothelium and leukocytes Blood collection, preparation of washed platelets, and cell labeling to those cells, potentially leading to the development of thrombosis and atherosclerosis [23] [24] [25] [26] . We hypotheBlood samples were obtained before the start of treatsized that an enhancement of PMP generation-if it ment at the first HD of the week in the HD patients, or exists-may participate in thrombogenesis and compenwhen patients visited the hospital for their regular medisation for the bleeding tendency in uremia.
cal examination in the CAPD or pre-dialyzed patients. This study used flow cytometry [13, 14, 18 ] to evaluate Two milliliters of venous blood were placed into a tube the PMPs in healthy subjects and three types of uremic containing 0.2 mL of an EDTA-ACD solution [ethylenediaminetetraacetic acid (EDTA)-2 Na 1.0 g, trisodium patients: those who were pre-dialyzed, on hemodialysis citrate 2.2 g, citric acid 807 mg, dextrose 2.2 g in 100 mL (HD), and on continuous ambulatory peritoneal dialysis of distilled water] and gently inverted twice. Platelet-(CAPD) therapy. The procoagulant activity of PMPs rich plasma (PRP) was prepared by centrifugation at were especially evaluated by annexin V, a placental pro-180 ϫ g for 20 minutes at room temperature. An aliquot tein with a high affinity and specificity for aminophos-(15 L) of the PRP that had been diluted up to 50 L pholipids, which has been shown to be an appropriate with 0.1% EDTA-saline was then incubated with 2 L probe for detecting such specific activity of PMPs [27] .
of FITC-GPIb and PE-annexin V for 30 minutes at room In addition, the concomitant influences of the HD procetemperature in the dark. Nonspecific FITC-labeled mAb dure, existence of internal arteriovenous (AV) fistula, and was used for the negative controls. chronic recombinant human erythropoietin (rHuEPO) therapy on PMP formation were studied.
Flow cytometry
Samples were analyzed using a flow cytometer (FACS Calibur; Becton Dickinson). The light scatter and fluo-METHODS rescence channels were set at a logarithmic gain. The to FITC-GPIb (R1) were gated on the side scatter (SSC) annexin V was purchased from Pharmingen (San Diego, dot plot versus fluorescence-1 (FL-1) profile, which was CA, USA). Isotype-matched mAbs of irrelevant specidetermined by comparing with the dot plot profile of ficity (FITC-labeled mouse IgG) were purchased from the samples treated with non-labeled mAb to GPIb Becton Dickenson (San Diego, CA, USA). Calibrated (Fig. 1A) . Regions corresponding to PMPs (R3) were latex beads (SPHERO Fluorescent Particles) were purthen discriminated from the platelet islet contaminated chased from Pharmingen.
(R2) by reviewing the cells in the gate R1 on SSC dot plot versus the forward scatter (FSC) dot plot profile Subjects (Fig. 1B) . A known number of fluorescent latex beads Twenty-nine healthy subjects and 46 HD patients, 23 (30,000) were added to each sample tube before analysis CAPD patients, and 20 pre-dialyzed uremic patients [30] , and the time of analysis was defined by counting a were studied. Diabetic patients were not included to pre-determined bead number (300 counts). The percentage of PMPs positive for PE-annexin V in the cells of estimate the simple influence of uremia on PMP generathe gate R3 was evaluated on histograms ( Fig. 1C ) contion [29] . Patients who had been receiving anti-platelet structed by the analysis software, CellQuest (Beckton drugs were excluded. The subjects' profiles are shown Dickinson). The bar was determined as the specific posiin Table 1 . Each patient population was matched for age tive region of PE-annexin V. The particles in the R3 with the healthy population (mean age, 52.3 Ϯ 5.19 years).
were designated as crude PMPs. The absolute number A majority of the dialysis patients had been treated with of PMPs stained by annexin V was calculated by the recombinant human erythropoietin (rHuEPO), which was following formula: intravenously injected three times a week in the HD patients, and subcutaneously administered once a week Counts of specific PMPs in the CAPD and pre-dialyzed patients. The HD patients ϭ (crude PMP counts in the gate R3) were dialyzed using columns of different types of membrane materials: polysulfone, cellulose-triacetate, or poly-ϫ (percentage of the stained methylmethacrylate. Heparin, as an anticoagulant agent, cells in the gate R3) ϫ 0.01. was continuously injected at a dose of 600 to 800 units per hour during HD treatment.
These specific PMPs with procoagulant activity were Each patient population was matched for age with the controls. The significant differences were obtained between each uremic group and the controls. The PMP counts were not different among three types of uremic patients. Statistically significant difference is marked. **P Ͻ 0.01 vs. control.
simply designated as "PMPs" in the following description unless otherwise stated. The study was approved by the institutional review board of the hospital and was carried out according to the principles of the Declaration of Helsinki. Informed consent was obtained from all of the subjects included in this study.
Statistics
Data were expressed as mean Ϯ SD unless otherwise stated. The differences between mean values were evaluated by the two-tailed Student t test for comparing two groups and by the analysis of variance (ANOVA) followed by Bonferroni-Dunn for comparing more than three groups. P Ͻ 0.05 was considered statistically significant.
RESULTS

PMP counts in uremic patients
The PMP counts were studied in 89 non-DM uremic patients and 29 age-matched controls. The PMP counts were significantly higher in each uremic group (pre-dialyzed, 142.3 Ϯ 49.5; HD, 195.3 Ϯ 103.1; CAPD, 161.0 Ϯ 47.9) than in the controls (104.9 Ϯ 46.3). The PMP counts were not different among three types of uremic groups (Fig. 2) . The PMP counts did not correlate with platelet between recombinant human erythropoietin (EPO) recipients and nongroup with thrombotic events than in those who had not experienced recipients in dialysis patients. The significant differences between the thrombotic events. Statistically significant difference is marked. **P Ͻ recipients and non-recipients were obtained in each subgroup of dialysis 0.01 vs. uremic group without thrombotic events.
patients. Statistically significant difference is marked. *P Ͻ 0.05 vs. nonrecipients.
counts and serum levels of albumin, urea nitrogen, and creatinine in any uremic group. rHuEPO recipients, as shown in Table 1 . No significant correlation was obtained between the PMP counts and PMP counts in uremic patients with and rHuEPO dose administered in each dialysis subgroup.
without thrombotic events
Regardless of rHuEPO use, the PMP counts were sig-A clinical link between PMP counts and thrombotic nificantly higher in the EPO non-recipients of HD (N ϭ events were examined in all uremic subjects. The throm-30; 148.9 Ϯ 80.5), CAPD (N ϭ 10, 138.0 Ϯ 34.3), and prebotic events were retrospectively investigated. Overall, dialyzed (N ϭ 18; 133.1 Ϯ 42.3) patients than in the the number of patients who had suffered thrombotic controls. In addition, PMP counts were significantly higher events for the last five years was 15 out of 89 patients (P ϭ 0.0260) even in the uremic patients without throm-(17.4%; 9 of 46 HD patients, 3 of 23 CAPD patients, botic events receiving no rHuEPO treatment (N ϭ 38, and 3 of 20 pre-dialyzed patients). The PMP counts in 131.6 Ϯ 48.7) than in the controls (N ϭ 29, 104.9 Ϯ 46.3). the patients with thrombotic events (248.5 Ϯ 91.1) were Influence of HD therapy on PMP generation significantly greater than in the patients without such events (159.5 Ϯ 74.5; Fig. 3) .
Changes in PMP counts during HD treatment. The time courses in PMP counts were examined in 14 HD patients Effects of rHuEPO on the PMP count before and 10 minutes, 30 minutes, and 2, 3, and 4 hours in dialysis patients after starting the HD treatment. Blood samples were The PMP counts were compared between the HD collected from the outlet port of the HD circuit tube patients receiving chronic rHuEPO treatment (recipibefore the dialysis column. The counts of PMP did not ents; 220.0 Ϯ 106.5, N ϭ 30) and those receiving no such significantly change during HD treatment. The data are treatment (non-recipients; 148.9 Ϯ 80.5, N ϭ 16). The shown in Figure 5A . PMP counts of the EPO recipients were significantly Changes in PMP count before and after dialysis colhigher than those of the EPO non-recipients (Fig. 4) .
umns. The changes of PMP counts before and after dialBoth groups were matched for age (59.2 Ϯ 12.8 vs. 55.4 Ϯ ysis columns were specially examined to better under-11.4 years old). The mean dose of rHuEPO used was stand the influence of blood contact with membrane 2380 Ϯ 921 units a week. Moreover, the significant differmaterials on PMP counts at two hours after the start of ence in the PMP counts between the EPO recipients HD. No significant changes in PMP counts were ob-(178.7 Ϯ 50.3, N ϭ 13) and non-recipients (138.0 Ϯ 34.3, served before and after the columns (before, 188.7 Ϯ N ϭ 10) was found in the subgroup of CAPD (Fig. 4) .
22.3; after, 193.1 Ϯ 41.5; Fig. 5B ). The HD membrane This comparative study was not done in the subgroup materials used were polysulfone (N ϭ 10) and cellulose triacetate (N ϭ 4). There were no significant differences of pre-dialysis patients because of the small number of ence in the PMP counts between the blood samples from the arms with and without AV fistula (Table 2) .
DISCUSSION
The major findings of this study are (1) the PMP counts were significantly elevated in a resting state in uremic patients such as pre-dialyzed, HD, and CAPD patients, compared with the age-matched healthy subjects, the PMP counts were not significantly different among three types of uremic groups; (2) the HD procedure and existence of internal AV fistula did not affect the PMP counts, but rHuEPO treatment was possibly involved in However, the primary cause of PMP elevation in uremia These studies were performed in 14 HD patients who used polysulfone (N ϭ 10) and cellulose triacetate (N ϭ 4) membrane materials. Data was not clarified in this study.
are expressed as mean Ϯ SE.
Our data showed that the counts of PMP enriched with procoagulant activity are elevated in non-diabetic uremic patients, as compared with the controls, regardless of uremic stages or dialysis modality. Nomura et al between the data of two types of membrane materials previously showed that PMP counts were increased in (data not shown).
uremic patients [31, 32] , which was likely to support our Influence of internal AV fistula on PMP counts current results. However, their data were deficient in several points. The profiles of their uremic subjects did This examination was performed in 10 HD patients not include the stage of uremia, modality of dialysis, with an internal AV fistula. Blood samples were obtained ages, and complications (for example, diabetes mellitus). from upstream veins close to AV fistula and almost siMoreover, their data were based upon so-called crude multaneously obtained from cubital veins of the opposite arm without AV fistula. There was no significant differPMPs that might include a lot of debris and non-func-tioning PMPs, as we described in our Methods section. We propose that a uremic milieu itself may cause an increase in circulating PMPs. High shear stress by a coneIn contrast, we clarified the patients' characteristics and identified vesicles with procoagulant activity as PMPs.
plate viscounter, which is thought to be most involved in the in vitro PMP formation, is analogous with clinical We believe that our current report is comprehensive and elaborates on the clinical significance of PMPs in uremic levels of fluid shear stress that may occur in atherosclerotic arteries [15] [16] [17] [18] [19] . It would be natural to think that patients.
Our study shows the biological relevance of elevated such physiological stress is easy to induce in uremic patients who commonly have hypertension and systemic PMP counts in uremia. PMPs provide competent surfaces for the assembly of coagulation factors and may arterio-atherosclerosis [8] . Alternatively, unknown uremic substances that are accumulated despite or by repetiinteract with components of the vessel walls, contributing to thrombus and atheroma formation [13, 14, [23] [24] [25] [26] .
tive dialysis treatment may additionally impact the process of PMP formation from activated platelets. Although the clinical significance of circulating PMPs in the pathogenesis of thrombotic diseases is not sufficiently
In conclusion, the counts of circulating PMPs were elevated in three types of uremic patients compared with acknowledged yet, recent clinical evidence indicates that an increase of circulating PMP counts is involved in the the healthy controls. The primary cause of PMP elevation was not clarified, but rHuEPO treatment could be incidence of ischemic heart diseases and cerebral strokes [20] [21] [22] . Our data show a positive link between PMP involved as an enhancer of PMP release. In a uremic setting overlapped by unfavorable factors such as uremic counts and thrombotic events in uremic patients, suggesting that an increase of PMP release in the circulatory toxins, pro-inflammatory cytokines, hypertension, and systemic atherosclerosis, an increase of PMPs may be a system underlies the high incidence of thrombotic diseases in uremic patients [7, 8] . Alternatively, PMP could potential trigger of acute thrombotic accidents, even under circumstances where the hemostatic functions of be a new marker or predictor of clinical thrombosis in uremia.
platelets are impaired. We expected that changes of PMP release might contribute to the pathogenesis of intra-dialyzer coagulation
